BPDCN Clinical Trial Information
for Healthcare Professionals
If you have a patient who has been diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN), whether or not they have received prior therapy,
THEY MAY BE ELIGIBLE TO PARTICIPATE IN A CLINICAL TRIAL STUDYING THE EXPERIMENTAL DRUG IMGN632.
See data on IMGN632 presented at the 62nd American Society of Hematology Annual Meeting and Exposition.
CD123 is expressed at high levels in BPDCN, making it a potential target for treatment. IMGN632 is an investigational antibody-drug conjugate consisting of a CD123-directed antibody linked to a DNA alkylating agent.
A phase 2 trial of IMGN632 is underway; it includes patients with front-line BPDCN and patients with relapsed or refractory BPDCN, with CR/CRc rate as the primary endpoint.1
IMGN632 was granted breakthrough therapy designation (BTD) by the US Food and Drug Administration (FDA) for treatment in BPDCN. This study is being performed in order to investigate safety and efficacy and to support a biologics license application for IMGN632 in this indication.
About the clinical Trial
This is an open-label, single arm, multi-center, phase 2 study to assess the safety and anti-BPDCN activity of IMGN632 when administered as monotherapy to patients with CD123+ disease.
All doses may be administered in an outpatient setting.
Key inclusion criteria
- Patients 18 years and older
- Patients with newly diagnosed BPDCN who have not received prior systemic therapy. These patients may have had
no therapy, or they may have received local therapy (radiotherapy, surgical excision, photodynamic therapy).
Eligible patients must have a recurrence or progression in the field of local therapy or disease outside the field of
- Patients with relapsed or refractory BPDCN who have received 1 to 3 prior lines of therapy
TO DISCUSS ELIGIBILITY FOR YOUR PATIENTS IN THIS CLINICAL TRIAL, CONTACT THE NEAREST CENTER DIRECTLY, OR CONTACT IMMUNOGEN MEDICAL AFFAIRS.
Click or tap to show/hide contact information.
Banner Health MD Anderson Cancer Center, Gilbert, AZ
Contact: Jana Bergelin, MS | 480-440-7458
Principal Investigator: Matthew Ulrickson, MD
City of Hope Medical Center, Duarte, CA
Contact: Ahmed Aribi, MD | 626-218-1133
Principal Investigator: Ahmed Aribi, MD
Moffitt Cancer Center, Tampa, FL
Contact: Christine Ternival | 813-745-2629
Principal Investigator: Kendra Sweet, MD
Dana-Farber Cancer Institute, Boston, MA
Contact: Daniel DeAngelo, MD | 617-632-2645
Roswell Park Cancer Institute, Buffalo, NY
Contact: Stephanie Halliwell | 716-845-4971
Contact: Eunice Wang, MD | 716-845-3544
Principal Investigator: Eunice Wang, MD
Duke Cancer Institute, Durham, NC
Contact: Rachel Stowe, BSN, RN | 919-681-4769
Contact: Susan Jones, BSN, RN | 919-681-4769
Principal Investigator: Harry Erba, MD, PhD
Baylor Scott & White University Medical Center, Dallas, TX
Principal Investigator: Moshe Y Levy, MD
MD Anderson Cancer Center, Houston, TX
Principal Investigator: Naval Daver, MD
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA
Contact: Rebecca White | 206-667-5226
Contact: Kaysey Orlowski | 206-667-1997
Principal Investigator: Roland Walter, MD
CAUTION: NEW DRUG—LIMITED BY FEDERAL (OR UNITED STATES) LAW TO INVESTIGATIONAL USE
Reference: 1. Clinicaltrials.gov. Study of IMGN632 in Patients with Relapsed/Refractory AML, BPDCN, ALL, Other CD123+ Hem Malignancies, NIH, August 2018. Accessed March 29, 2021. https://clinicaltrials.gov/ct2/show/NCT03386513.